NEW YORK, NY / ACCESSWIRE / March 31, 2017 / The Canadian gold companies will merge to share proceeds from the Chilean gold belt, a statement released by Goldcorp reveals. The joint venture will see the two companies jointly own property in the Maricunga region in Chile, with Goldcorp looking to increase investment in the area. Here’s a closer look at the two companies’ joint venture details.

RDI Initiates
Coverage:

Barrick Gold
Corporation https://ub.rdinvesting.com/news/?ticker=ABX

Goldcorp
Incorporation https://ub.rdinvesting.com/news/?ticker=GG

Barrick Gold Corporation’s stock dipped yesterday 1.82% to close the day at $18.84. The company had suffered a setback at Valadero, when one of the pipes carrying gold solutions ruptured. There was however no civilian casualty or environmental damages. The news comes almost immediately after the company announced a merger between it and Goldcorp.

Goldcorp agreed to take a 25% stake of Cerro Casale. With Barrick Gold already having 25% of Kinross Corp, it would mean both Canadian companies would own a 50% stake of the Chilean gold belt. Barrick went on to state that the agreement would allow them to direct capital elsewhere in their portfolio. This would in turn ensure investors’ options are expanded, especially with the largest undeveloped gold and copper deposits all over the world.

Access RDI’s Barrick Gold Research Report at: https://ub.rdinvesting.com/news/?ticker=ABX

Goldcorp ended the day on a low, with its stock dipping 1.68% to trade at $14.66. Goldcorp and Exeter Resource Corporation had earlier announced plans for Goldcorp to acquire Exeter by the way of a mutual agreement. The takeover would involve Goldcorp assuming control of all issued and outstanding shares.

The total considerations offered for all outstanding Exeter shares would be approximately $247 million. Each of the common Exeter shares outstanding would be exchanged for 0.12 in common stock of Goldcorp. Goldcorp also went on to form a joint venture with Barrick Gold. The shares are expected to face stabilization difficulties amid competition from Yamana Gold and IAMGOLD Corp.

Access RDI’s Goldcorp Research Report at: https://ub.rdinvesting.com/news/?ticker=GG

Our Actionable Research on Barrick Gold Corporation (NYSE: ABX) and Goldcorp Incorporation (NASDAQ: GG) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458642

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Conoco and Cenovus of Canada have worked out a deal that benefits both companies in the long term. The deal is expected to be completed by the end of the second quarter of this year. The two stocks went in opposite directions in Thursday’s trading.

RDI Initiates
Coverage:

ConocoPhillips https://ub.rdinvesting.com/news/?ticker=COP

Cenovus Energy Inc. https://ub.rdinvesting.com/news/?ticker=CVE

ConocoPhillips advanced 8.81% to close at $50 on Thursday. The stock traded between $50.41 and $48.61 on a volume of 40.06 million shares traded. The uptick was brought about by the company’s announcement that it would be selling most of its gas assets in Western Canada’s Deep Basin to Cenovus Energy. Another part of the deal was that Conoco would sell its 50% investment in the Foster Creek Christina Lake oil sands that is a cash and stock deal that totals $13.3 billion and from which $10.6 billion will be received in cash.

Although the sale of gas assets is likely going to impact ConocoPhillips’ revenue, with more cash availability from this deal, the company will be able to significantly deleverage its balance sheet by reducing debt to a level of $20 billion from the current level of nearly $26.2 billion and will also be able to repurchase more shares for a total of nearly $6 billion. The Oil and Gas industry has been facing turmoil in the last several years on account of decreasing revenues, higher cost and additionally higher leverage making investment unprofitable, ConocoPhillips is no exception to this. While revenues are still declining, the company has narrowed down losses in fiscal year 2016 to a GAAP loss of $3.6 billion, down from a GAAP loss of $4.4 billion in fiscal year 2015. A large number of investment firms have raised their recommendation of Conoco Philips stock from a “hold” to a “buy” rating.

Access RDI’s ConocoPhillips Research Report at: https://ub.rdinvesting.com/news/?ticker=COP

Cenovus Energy fell 13.69% to close at $11.29 on Thursday. The stock traded between $11.89 and $11.28 on a volume of 45.05 million shares traded. An integrated oil company that has its headquarters in Calgary, Alberta, agreed to terms with Conoco Phillips to a $13.3 billion cash and stock trade for the Deep Basin and Foster Creek Christina Lake assets. Although the transaction is going to be accretive on immediate basis for Cenovus doubling its total production and reserves, in order to make the deal work, Cenovus is likely to have to sell some of its short term profit assets.

The company is seeking financing for the sale from several banks by selling some of its currently producing oil properties. They have hired the Bank of Montreal to provide counsel on the sale of their Suffield oil and natural gas drilling project in Alberta. That sale is hoped to be about C$600 million. In addition, the company has selected two advisors – Barclays Plc and Canadian Imperial Bank of Commerce – for its sale of the Pelican Lake asset in Alberta seeking C$1.2 billion to raise cash for the Conoco deal. Additionally with Cenovus’ announcement on March 29th, a deal financing by issuing additional common shares for the amount in the range of C$3.0 billion to C$3.45 billion, is likely to dilute shareholder’s interest.

Access RDI’s Cenovus Energy Research Report at: https://ub.rdinvesting.com/news/?ticker=CVE

Our Actionable Research on ConocoPhillips (NYSE: COP) and Cenovus Energy Inc. (NYSE: CVE) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458644

IRVINE, CA / ACCESSWIRE / March 31, 2017 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Regulus Therapeutics, Inc. (“Regulus” or the “Company”) (NASDAQ: RGLS). Investors, who purchased or otherwise acquired shares between January 21, 2016 and June 27, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the April 3, 2017 lead plaintiff motion deadline.

If you purchased shares of Regulus during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The Complaint states that throughout the Class Period, Regulus made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. On June 27, 2016, the Company announced that it received notice from the U.S. Food and Drug Administration (“FDA”) that its new drug for the treatment of chronic hepatitis C virus infection, which was under FDA review, is now being put on clinical hold after a second serious case of jaundice was reported.

If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 458660

BOWIE, MD / ACCESSWIRE / March 31, 2017 / Old Line Bank (NASDAQ: OLBK) is honored to announce its participation in the Washington Suburban Sanitary Commission’s (WSSC) new Business Investment and Growth (BIG) program which aims to empower local businesses through lending initiatives in Montgomery and Prince George’s Counties (more information can be found at www.wsscwater.com/big). This program outlined a $12 million deposit commitment from WSSC into participating community banks that are located in Prince George’s and Montgomery Counties. Contributing community banks, like Old Line Bank, then leverage these deposits thus creating additional funds to lend to businesses within the communities they serve. “Old Line Bank has seen major growth in small businesses in Prince George’s and Montgomery Counties,” said James W. Cornelsen, President and Chief Executive Officer of Old Line Bank. “Our mission as a community bank is to invest in the people we serve by turning deposits into loans that directly stimulate local businesses and support our local non-profits through service and contributions.”

WSSC has modeled this program to follow the blueprint of other successful reinvestment programs instituted in both aforementioned counties. According to the WSSC, by depositing this $12 million in community banks, they will leverage the deposits “2:1 to generate $24 million in available funds to be lent to small and local businesses.” “WSSC is proud to partner with Old Line Bank and expand opportunities for local businesses to access capital needed to grow and thrive,” said WSSC General Manager and CEO, Carla A. Reid. “When local businesses succeed, our local economy succeeds.”

Old Line Bank was established in 1989 and is headquartered in Prince George’s County, MD, making it a central resource for business banking in the area. Extra initiatives to grow the local economy are at the forefront of Old Line Bank’s business model. With an annual growth rate of 18% in funded business loans between 2015 and 2016, Old Line Bank continues to be a leader when it comes to small business development and local lending.

In April, both WSSC and Old Line Bank will also participate in WETATi’s (We’re Empowered To Achieve The impossible) Entrepreneurship Empowerment Competition convention. This competition is designed to identify and support local entrepreneurs, the next generation of aspiring millennials, in developing business plans and provide financial awards to assist with startup costs. The convention, scholarship and grants award will be held April 22-23 at the Colony Ballroom and Nyumburu Cultural Center, the University of Maryland, College Park. For more information about this event please visit www.wetaticonvention.com; or email info@wetati.com.

Old Line Bancshares, Inc. (NASDAQ: OLBK) is a parent company of Old Line Bank, a Maryland chartered commercial bank headquartered in Bowie, Maryland. Old Line Bank’s reach spans the Baltimore-Washington corridor, with 21 branch locations in its current market area of eight suburban Maryland counties, inclusive of Anne Arundel, Baltimore, Calvert, Carroll, Charles, Montgomery, Prince George’s and St. Mary’s.

For additional information, please visit our website at www.oldlinebank.com or call 301-430-2500.

CONTACT:

James W. Cornelsen, President and Chief Executive Officer

SOURCE: Old Line Bancshares, Inc.

ReleaseID: 458659

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / TrovaGene and NewLink Genetics stock rose in Thursday’s trading session as both companies caught the attention of investors after optimism about their current FDA Phase progress.

RDI Initiates
Coverage:

TrovaGene Inc. https://ub.rdinvesting.com/news/?ticker=TROV

NewLink Genetics
Corp. https://ub.rdinvesting.com/news/?ticker=NLNK

TrovaGene advanced 9.52% to close at $1.15 on Thursday. The stock traded between $1.15 and $1.05 on volume of 171,426 178,012 shares traded. The company, a biotechnology company, develops oncology therapeutics for improved cancer care, announced that it is to present at the MicroCap Conference to be held on April 4, 2017 in New York City.

In its 4th quarter financial report, the company showed a net loss of $8.5 million or $0.34 per diluted share, which has narrowed down significantly from net loss of $10.2 million reported in the 3rd quarter of 2016, but is higher than the loss of $7.4 million reported in the fourth quarter of 2015. Operations had the biggest drag on the company bottom line, as they increased to nearly $9.9 million from $7.5 million of the same period of report in 2015. At the end of December 31, 2016, Trovagene had approximately $37.9 million in cash assets available for operations.

Access RDI’s TrovaGene Research Report at: https://ub.rdinvesting.com/news/?ticker=TROV

NewLink Genetics advanced 5.62% to close at $23.12 on Thursday. The stock traded between $24.85 and $22.835 on a volume of 1.06 million shares traded. The surge in price came after Peter Lawson of SunTrust Robinson Humphrey upgraded the company from “hold” to “buy” and raised the price target to $30 from a previous target of $12, and expressed his view that NewLink is “well positioned” to become a potential takeover target. Potential positive news from ongoing product trials after having gone through a major setback earlier. The company’s IDO-inhibitor space therapies target cancer patients, and NewLink has a unique position as it is virtually alone in its pursuit of IDO-inhibitor solutions.

Newlink has a mix of “buy” and “hold” ratings from small numbers of investment research firms, with consensus ratings as “overweight” and Thursday’s advances has resulted in the stock to went rising more than 120% in 2017.

Access RDI’s NewLink Genetics Research Report at: https://ub.rdinvesting.com/news/?ticker=NLNK

Our Actionable Research on TrovaGene Inc. (NASDAQ: TROV) and NewLink Genetics Corp. (NASDAQ: NLNK) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458650

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Rosetta Genomics and Halozyme Therapeutics both posted losses in Thursday’s trading session, on events that were outside of their control. Rosetta saw its earnings results post another loss while finding additional outside sources of revenues, while Halozyme had an unexpected pause brought to their FDA clinical trial expectations.

RDI Initiates
Coverage:

Rosetta Genomics Ltd. https://ub.rdinvesting.com/news/?ticker=ROSG

Halozyme
Therapeutics, Inc. https://ub.rdinvesting.com/news/?ticker=HALO

Rosetta Genomics fell 16.72% to close at $2.79 on Thursday. The stock traded between $3.35 and $2.79 on a volume of 217,823 shares traded. The company focuses on genomic diagnostics designed to improve treatment decisions through making timely and accurate diagnostic information available to physicians. The company’s main product is the RosettaGX Reveal, a unique microRNA classifier for diagnosis of cancer in indeterminate thyroid nodules.

In financial news, the company made available its 4th quarter financial results. It had raised $4.6 million through one prominent institutional healthcare investor. Rosetta has posted a 4th quarter GAAP loss of $4.8 million or $2.73 a share as compared to $6.7 million or $4.39 a share for the 4th quarter of 2015. The company has also improved its operating losses from $5.1 million in Q4 2015 to $4.3 million in Q4 2016 while reducing R&D expenses by nearly $200,000 compared to the same reporting period a year ago.

RosettaGX Reveal remains the company’s future revenue source as the company expects revenues of $4 million to $5 million from RosettaGX Reveal in fiscal year 2017. The Journal of Clinical Pathology, a peer-reviewed journal, published a favorable clinical validation of RosettaGX Reveal. The product was also a cover feature on another peer reviewed journal, Cancer Cytopathology.

Access RDI’s Rosetta Genomics Research Report at: https://ub.rdinvesting.com/news/?ticker=ROSG

Halozyme Therapeutics dropped 8.82% to close at $13.03 on Thursday. The stock traded between $13.29 and $12.44 on a volume of 5.94 million shares traded. In its latest update on March 29th, Halozyme management has expressed hope that the company would be able to have its PEGPH20 plus modified FOLFIRINOX chemotherapy treatment evaluated soon, as they were informed by SWOG, an independent network of researchers that all entries to the Phase I/II studies have been temporarily closed.

On Wednesday, March 29th, the Oncologic Drug Advisory Committee of the FDA voted 11 – 0 that the benefit/risk of rituximab/hyaluronidase for subcutaneous (under the skin) injection was favorable for patients. The drug is co-formulated with Halozyme’s recombinant human hyaluronidase and was approved for use in Europe in 2014. Currently it is marketed as a subcutaneous formula of rituximab.

Access RDI’s Halozyme Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=HALO

Our Actionable Research on Rosetta Genomics Ltd. (NASDAQ: ROSG) and Halozyme Therapeutics, Inc. (NASDAQ: HALO) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458647

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Advances in technology and increased bandwidth speeds have been responsible for easy and affordable access to Internet gaming for people around the world. Apps from social media to mobile games have seen increased interest and competition from a number of vendors. These are two companies who are looking to find their niche in these markets.

RDI Initiates
Coverage:

NQ Mobile Inc. https://ub.rdinvesting.com/news/?ticker=NQ

Zynga Inc. https://ub.rdinvesting.com/news/?ticker=ZNGA

NQ Mobile advanced 7.05% to close at $4.10 on Thursday. The stock traded between $4.40 and $4.02 on a volume of 2.47 million shares traded. The upswing was the result of an agreement with Tsinghua Tongfang of China to complete the FL Mobile Divestment and the sale of Showself’s Live social video business. Tsinghua Tongfang will get a 63% equity interest in FL Mobile for a cash consideration of RMB2,520 million (Approximately $365.35 million USD) and a 65% equity interest in Beijing Showself for RMB800 million (Approximately $116 million USD) in cash.

Additionally, the terms of the agreement require Tsinghua Tongfang to pay RMB150 million (Approximately $21.75 million USD) in cash as a non-refundable earnest payment that will be applied towards payment of the purchase price. The remaining balance will be paid on or before May 31, 2017 once NQ Mobile delivers all of its equity interests in FL Mobile and Beijing Showself.

NQ Mobile is a global provider of mobile Internet services.

Access RDI’s NQ Mobile Research Report at: https://ub.rdinvesting.com/news/?ticker=NQ

Zynga advanced 1.77% to close at $2.88 on Thursday. The stock traded between $2.95 and $2.825 on a volume of 22.85 million shares traded. The gains came as the result of the company’s announcement of the March 16th launch of Boggle With Friends. This latest addition to Zynga’s “With Friends” series, developed in collaboration with Hasbro, is a free-to-play game, designed for iPhone, iPad and Android devices, the app can be immediately downloaded from the App Store or Google play.

Zynga, the creator of Farmville and Texas HoldEm Poker was considered a hot stock in the 2012 IPO market, and it has subsequently lost its shine thereafter. It is just one of a number of companies who is trying to capitalize on the consistent growth of the mobile gaming industry. The company has narrowed down its losses to $35.4 million and $108.2 million for the fourth quarter and full year of 2016 respectively. With the increase in advertising revenue, the company has managed to narrow down its decline in its revenue with revenue of $741.4 million for the year 2016 as compared to revenue of $764.7 million reported for the year 2015. However, the decline in gaming revenue is still a concern for the company and investors, and with the launch of “Boggle with Friends”, investors may be hopeful for better revenue growth. Zynga has reported $190.5 million revenue in the fourth quarter of 2016 and it expects revenue of $185 million and a net loss of $16 million for the current quarter.

Access RDI’s Zynga Research Report at: https://ub.rdinvesting.com/news/?ticker=ZNGA

Our Actionable Research on NQ Mobile Inc. (NYSE: NQ) and Zynga Inc. (NASDAQ: ZNGA) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458646

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Prana Biotechnology and Xenetic Biosciences both saw their company’s stock prices soar on news of a broader, more global product distribution. Prana is continuing to expand its presentation of PBT-434, while Xenetic is moving ahead with its strategic planning goals to make its product technology available to a larger geographical area.

RDI Initiates
Coverage:

Prana Biotechnology
Limited https://ub.rdinvesting.com/news/?ticker=PRAN

Xenetic Biosciences
Inc. https://ub.rdinvesting.com/news/?ticker=XBIO

Prana Biotechnology advanced 37.65% to close at $3.40 on Thursday. The stock traded in a wide range between $4.58 and $2.75 during the day on a volume of 11.95 million shares traded. The company has presented new data from its Reach2HD trial at the American Neurological Association Annual Meeting held in Baltimore. Its primary candidate drug, PBT-434, demonstrated pre-clinical evidence that the drug will help with the treatment of movement disorders of patients with Parkinson’s Disease.

Prana Biotechnology, an Australian company, for the half-year period ending December 31, 2016, reported total operating expenses of $6.05 million AUD, a pre-tax income of $3.65 million AUD, and a loss of $0.68 AUD per share.

Access RDI’s Prana Biotechnology Research Report at:
https://ub.rdinvesting.com/news/?ticker=PRAN

Xenetic Biosciences accelerated to advance 44.30% to close at $5.44 on Thursday. The stock traded between $5.61 and $3.87 on volume of 180,793 shares traded. Xenetic has been aggressively promoting its products internationally, and the rise in price is due in part to it becoming a member of the NASDAQ community on March 30th. The company has been expanding its patent portfolio to a number of countries, including Europe and the United States. Currently, their major marketable product is PolyXen technology platform. The product’s IP on its PolyXen technology platform will afford protection on average for the next 10 to 12 years.

The latest financial report with period ending September 30, 2016, showed the company posting $2.25 million in operating expenses, a net loss of $2.47 million, and net loss per share of $0.28 and it had about $212,000 of cash assets on its books as on September 30th.

Access RDI’s Xenetic Biosciences Research Report at:
https://ub.rdinvesting.com/news/?ticker=XBIO

Our Actionable Research on Prana Biotechnology Limited (NASDAQ: PRAN) and Xenetic Biosciences Inc. (NASDAQ: XBIO) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458648

SAN JOSE, CA / ACCESSWIRE / March 31, 2017 / iSign Solutions Inc. (“iSIGN”) (OTCQB: ISGN), a leading supplier of electronic signature and other software solutions enabling secure and cost-effective management of document-based digital transactions, today reported total revenue of $1,065,000 for the year ended December 31, 2016, a decrease of $555,000, or 34%, compared to total revenue of $1,620,000 for the prior year.

“During 2016, we significantly reoriented our go-to-market approach in favor of engagements with partners capable of generating recurring revenue transactions from many of their existing customers,” said Philip Sassower, Co-chairman and Chief Executive Officer for iSIGN. “Because of this commitment to channel partner electronic signature solutions, we reduced our direct sales efforts and related marketing support. These actions, in part, enabled a significant reduction in our year-over-year burn rate and contributed to the reduction in net loss attributed to common shareholders, which was lowered by a third. Likewise, our development efforts have been redoubled in support of partner integration and customized iSIGN platform solutions, together with continuing support for our important, existing customers in the financial services sector. Because of these focused efforts, we reduced our R&D expenses by 25% year-over-year. Our restructuring adjustments indicate a sharper focus on multi-year partnerships expected to yield significant recurring revenue transaction volume over time, while reducing our expense run rate.”

For the year ended December 31, 2016, operating expenses were $4,274,000, a decrease of $1,171,000, or 22%, compared to operating expenses of $5,445,000 in the prior year. This decrease primarily was due to iSIGN’s efforts to restructure its operations in favor of partner-generated recurring revenue.

For the year ended December 31, 2016, the net loss attributable to common stockholders was $5,057,000, a decrease of $2,562,000, or 34%, compared to a net loss attributable to common stockholders of $7,619,000 in the prior year. This decrease primarily was due to a $616,000 decrease in loss from operations from 2015 to 2016, resulting from the above-mentioned decrease in operating expenses offset by the decrease in revenue, a $312,000 increase in gain on derivative liability, a $281,000 decrease in accretion of beneficial conversion feature and a $1,863,000 decrease in preferred stock dividend expense, offset by a $164,000 increase in interest expense and a $337,000 increase in amortization of debt discount.

Additional financial information regarding iSIGN’s operating results for the year ended December 31, 2016, will be available in the Company’s Annual Report on Form 10-K that will be filed with the Securities and Exchange Commission and available at www.sec.gov.

ABOUT iSIGN

iSIGN (formerly known as Communication Intelligence Corporation or CIC) is a leading provider of digital transaction management (DTM) software enabling fully digital (paperless) business processes. iSIGN’s solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated software platform for both ad-hoc and fully automated transactions. iSIGN’s software platform can be deployed both on-premise and as a cloud-based service, with the ability to easily transition between deployment models. iSIGN is headquartered in Silicon Valley. For more information, please visit our website at www.isignnow.com. iSIGN’s logo is a trademark of iSIGN.

FORWARD LOOKING STATEMENTS

Certain statements contained in this press release, including without limitation, statements containing the words “believes,” “anticipates,” “hopes,” “intends,” “expects,” and other words of similar import, constitute “forward looking” statements within the meaning of the Private Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors, which may cause actual events to differ materially from expectations. Such factors include the following (1) technological, engineering, quality control or other circumstances which could delay the sale or shipment of products containing the company’s technology; (2) economic, business, market and competitive conditions in the software industry and technological innovations which could affect customer purchases of the company’s solutions; (3) the company’s inability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others or prevent others from infringing on the proprietary rights of the company; and (4) general economic and business conditions.

Contact Information:

iSIGN
Andrea Goren
Chief Financial Officer
+1.646.763.8363
agoren@isignnow.com

SOURCE: iSign Solutions Inc.

ReleaseID: 458610